News | November 13, 2007

PAD Diagnosis Driving Peripheral Stents In Europe

November 14, 2007 - The European peripheral stents market is in the developmental phase, both in terms of revenue and technology due to improved diagnosis of peripheral arterial disease (PAD), according to a study released by Frost & Sullivan.

New analysis from Frost & Sullivan, European Peripheral Stents Market, indicates that the greater awareness of PAD and of available treatments will promote market expansion. Additionally, studies demonstrating the efficacy of novel product offerings will reinforce growth trends in the market. The report finds that the market earned revenues of USD 160.7 million in 2006 and estimates this to reach USD 376.2 million in 2013.

“The move towards minimally invasive surgeries and the rising incidence of peripheral arterial disease has increased the need for stenting,” noted Frost & Sullivan Research Analyst Sowmya Rajagopalan. “Research and innovation have been the norm in this developing market, with shortcomings in existing products being rapidly addressed to ensure their success.”

At the same time, manufacturers have moved to boost revenues by developing products for new applications. The launch of dedicated below the knee (BTK) stents is the best example of the emergence of new application areas. The need to treat arterial disease in the narrow arteries lying below the knee was studied along with the drawbacks of using coronary stents for this purpose. This led to the need for dedicated stents, resulting in the development of BTK stents.

However, as the use of stents in peripheral applications is new in comparison to coronary stents, and because surgical procedures have been the gold standard for the treatment of PAD, the acceptance of these products has been relatively low. Moreover, a sizeable percentage of the patient base remains untreated, resulting in an under exploitation of the potential patient pool and, in turn, limiting revenues.

"There is a dearth of sufficiently trained surgeons to perform these procedures," says Rajagopalan. "The lack of training is resulting in improper stenting, thereby affecting the success of both the procedures and products."

To promote sustained market expansion, manufacturers should conduct symposiums and workshops to enhance awareness among patients and physicians about peripheral arterial disease and peripheral stents.

Source: Frost & Sullivan

For more information:

Related Content

First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
TOBA II BTK clinical trial, Intact Vascular, Tack Endovascular System, CLI, critical limb ischemia, first patient treated
News | Stents Peripheral| March 02, 2017
Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Biotronik, Pulsar-18 bare metal self-expanding stent, BMS SE, BIOFLEX PEACE trial, 12-month results, VEITHsymposium 2016
News | Stents Peripheral| December 13, 2016
Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (...
LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) included 11 late-breaking trials and 16 first repor
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
Overlay Init